Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now
Frankfurt - Delayed Quote EUR

Amgen Inc. (AMG.F)

Compare
294.00
-4.20
(-1.41%)
At close: March 5 at 7:07:17 PM GMT+1
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
33,424,000
33,424,000
28,190,000
26,323,000
25,979,000
Cost of Revenue
12,858,000
12,858,000
8,451,000
6,406,000
6,454,000
Gross Profit
20,566,000
20,566,000
19,739,000
19,917,000
19,525,000
Operating Expense
13,308,000
13,308,000
11,842,000
10,351,000
10,381,000
Operating Income
7,258,000
7,258,000
7,897,000
9,566,000
9,144,000
Net Non Operating Interest Income Expense
-3,155,000
-3,155,000
-2,875,000
-1,406,000
-1,197,000
Other Income Expense
506,000
506,000
2,833,000
-814,000
-1,246,000
Pretax Income
4,609,000
4,609,000
7,855,000
7,346,000
6,701,000
Tax Provision
519,000
519,000
1,138,000
794,000
808,000
Net Income Common Stockholders
4,090,000
4,090,000
6,717,000
6,552,000
5,893,000
Diluted NI Available to Com Stockholders
4,090,000
4,090,000
6,717,000
6,552,000
5,893,000
Basic EPS
7.89
7.62
12.56
12.18
10.34
Diluted EPS
7.83
7.56
12.49
12.11
10.28
Basic Average Shares
536,500
537,000
535,000
538,000
570,000
Diluted Average Shares
540,250
541,000
538,000
541,000
573,000
Total Operating Income as Reported
7,258,000
7,258,000
7,897,000
9,566,000
7,639,000
Total Expenses
26,166,000
26,166,000
20,293,000
16,757,000
16,835,000
Net Income from Continuing & Discontinued Operation
4,090,000
4,090,000
6,717,000
6,552,000
5,893,000
Normalized Income
4,090,000
4,090,000
6,717,000
6,552,000
7,215,895
Interest Expense
3,155,000
3,155,000
2,875,000
1,406,000
1,197,000
Net Interest Income
-3,155,000
-3,155,000
-2,875,000
-1,406,000
-1,197,000
EBIT
7,764,000
7,764,000
10,730,000
8,752,000
7,898,000
EBITDA
13,356,000
13,356,000
14,801,000
12,169,000
11,296,000
Reconciled Cost of Revenue
12,858,000
12,858,000
8,451,000
6,406,000
6,454,000
Reconciled Depreciation
5,592,000
5,592,000
4,071,000
3,417,000
3,398,000
Net Income from Continuing Operation Net Minority Interest
4,090,000
4,090,000
6,717,000
6,552,000
5,893,000
Total Unusual Items Excluding Goodwill
--
--
--
--
-1,505,000
Total Unusual Items
--
--
--
--
-1,505,000
Normalized EBITDA
13,356,000
13,356,000
14,801,000
12,169,000
12,801,000
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
--
--
--
--
-182,105
12/31/2021 - 1/3/2000

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

AZN.L AstraZeneca PLC
12,062.00
-0.02%
 
GRFS Grifols, S.A.
8.71
+5.32%
 
SAN.PA Sanofi
108.80
-0.46%
 
ROG.SW Roche Holding AG
303.20
-0.33%
 
BAYN.DE Bayer Aktiengesellschaft
24.49
+4.12%
 
AZN AstraZeneca PLC
77.96
+0.92%
 
NVO Novo Nordisk A/S
90.86
+3.84%
 
MRK Merck & Co., Inc.
93.19
+0.68%
 
GILD Gilead Sciences, Inc.
115.44
+0.61%
 
LLY Eli Lilly and Company
929.72
+2.05%